An interventional study of Smartphone application and low-dose computed tomography in Smoking Cessation, sponsored by Oulu University Hospital. Recruiting at 5 sites in Finland. Open to participants aged 50 Years to 74 Years. Per ClinicalTrials.gov, last updated 2026-02-06.
Sponsored by Oulu University Hospital · Not applicable, Interventional, and Treatment
The study investigates effectiveness of different smoking cessation methods and low-dose CT based lung cancer screening
The study population consists of individuals aged 50-74 years with a significant smoking history who continue to smoke. The study design is a prospective and participants are randomized into three study arms: low-dose CT (LDCT) + smoking cessation with a smartphone application (arm 1), LDCT + smoking cessation with written materials (arm 2), smoking cessation with a smartphone application without LDCT (arm 3). The study compares effectiveness of smoking cessation methods, LDCT in lung cancer screening, lung cancer stage distribution, and lung cancer specific survival.
1,581 studies on the registry are indexed under Smoking Cessation; 198 are open to participants now.
This study's planned enrollment of 1,200 is above the median of 164 across 1,423 interventional studies indexed under Smoking Cessation.
Browse Smoking Cessation studies →Oulu University Hospital is the lead sponsor of 40 studies on the registry; 17 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Smoking cessation with a smartphone application + LDCT lung cancer screening
Other: Smartphone application · Other: low-dose computed tomography
Smoking cessation with written materials + LDCT lung cancer screening
Other: low-dose computed tomography · Other: Written materials for smoking cessation
Smoking cessation with a smartphone application without LDCT lung cancer screening
Other: Smartphone application
Suunta smartphone application for smoking cessation
Low-dose computed tomography based screening for lung cancer
Written materials for smoking cessation
Rate of smoking cessation
The percentage of participants who have quitted smoking between the study arms 1 vs. 2
Time frame: three months
Rate of smoking cessation
The percentage of participants who have quitted smoking between all the study arms
Time frame: Three months
Rate of smoking cessation
The percentage of participants who have quitted smoking between all the study arms
Time frame: 12 and 24 months
Rate of long-term smoking cessation
The percentage of participants who have had abstinence of smoking for at least six months
Time frame: 12 and 24 moths
LDCT findings
The percentage of LDCT negative, indetermined, and positive findings by screening round
Time frame: baseline and 24 months
Sensitivity and specificity of LDCT screening examination
Sensitivity and specificity of LDCT screening examination for lung cancer detection (arms 1\&2 vs. 3)
Time frame: 24 months, 36 months, and 10 years
Lung cancer incidence
Lung cancer incidence (stage specific) (arms 1\&2 vs. 3)
Time frame: 24 months, 36 months, and 10 years
Frequency of self-reported smoking cessation verified with CO measurement
Frequency of self-reported smoking cessation verified with CO measurement
Time frame: 24 months
Plan to share: Yes — De-identified individual participant data underlying the results reported in this article will be shared.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: The data will be available beginning 6 months after publication and ending 3 years thereafter.
Access criteria: Data will be shared with qualified researchers who submit a methodologically sound proposal for analyses that align with the original study aims. Proposals should be submitted to the corresponding author. Access will require a data use agreement.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Oulu University Hospital